TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24865680

Group type: EXPERIMENTAL
Intervention: Sawyer PointONE filters
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Sawyer PointONE filters and WASH BCC
Number of subjects: 952

Group type: COMPARATOR
Intervention: WASH BCC
Number of subjects: 952
Study: 21839620

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Number of subjects: 0
Study: 18783876

Group type: EXPERIMENTAL
Intervention: UNS RP plus sural nerve grafting (SNG)
Number of subjects: 107

Group type: COMPARATOR
Intervention: UNS RP alone (Control)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: UNS RP plus SNG
Number of subjects: 107
Study: 16782102

Group type: EXPERIMENTAL
Intervention: SP6 acupressure
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo group (light touch on SP6 acupoint)
Number of subjects: 58
Study: 15072399

Group type: EXPERIMENTAL
Intervention: Lateral approach to sciatic nerve block with 1% mepivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Posterior approach to sciatic nerve block with 1% mepivacaine
Number of subjects: 60
Study: 11668312

Group type: EXPERIMENTAL
Intervention: Doxycycline (150 mg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 32
Study: 9852980

Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7780294

Group type: EXPERIMENTAL
Intervention: 40‐mg intravenous cocaine injections
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 3182119

Group type: EXPERIMENTAL
Intervention: Tulobuterol (2 mg, twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fenoterol (2.5 mg, thrice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tulobuterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenoterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 0
Study: 31010703

Group type: EXPERIMENTAL
Intervention: Leap Motion Controller-based training (LMCBT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 103
Study: 29676673

Group type: EXPERIMENTAL
Intervention: Depo-Medrol (DEPO)
Number of subjects: 104

Group type: COMPARATOR
Intervention: No Depo-Medrol (NODEPO)
Number of subjects: 104
Study: 27324086

Group type: EXPERIMENTAL
Intervention: Free gaze condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed gaze condition
Number of subjects: 0
Study: 24820831

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (10 billion cfu/day for five days)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control (no probiotic medication)
Number of subjects: 2000
Study: 22285946

Group type: EXPERIMENTAL
Intervention: 150 mg CLMWF
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20583960

Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (TURP)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection in saline (TURIS)
Number of subjects: 518
Study: 18669464

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg orally once daily for 4 weeks, followed by 2 weeks off)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Interferon alfa (9 million units subcutaneous injections, three times weekly)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 750
Study: 15904908

Group type: EXPERIMENTAL
Intervention: Zinc gluconate supplementation with IFN-alpha-2a/ribavirin
Number of subjects: 40

Group type: COMPARATOR
Intervention: IFN-alpha-2a/ribavirin without zinc supplementation
Number of subjects: 40
Study: 12736474

Group type: EXPERIMENTAL
Intervention: Torasemide at 4-8 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Furosemide at 20-40 mg/day
Number of subjects: 50
Study: 10230947

Group type: EXPERIMENTAL
Intervention: Calcium chloride (CaCl2) 10 mg/kg administered simultaneously with propofol
Number of subjects: 58

Group type: COMPARATOR
Intervention: Saline administered simultaneously with propofol
Number of subjects: 58
Study: 8653836

Group type: EXPERIMENTAL
Intervention: CNP at 500 pmol/min
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hydralazine at 10 μg/min (control)
Number of subjects: 16
Study: 7904993

Group type: EXPERIMENTAL
Intervention: Roxatidine 75 mg twice daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cimetidine 200 mg 3 times a day and 400 mg at bed time
Number of subjects: 47
Study: 3327445

Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin 0.35 mg/kg followed by an infusion of 0.07 mg/kg/h for 24 h
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31948661

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid (O-3FA) 4 g/day
Number of subjects: 325

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 325
Study: 29580591

Group type: EXPERIMENTAL
Intervention: Aromatherapy (AT)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 254
Study: 28479218

Group type: EXPERIMENTAL
Intervention: BMI screening and reporting
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: BMI screening only
Number of subjects: 79

Group type: COMPARATOR
Intervention: No BMI screening or reporting
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: BMI reporting (BMI results alone or both BMI and fitness test results)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: BMI reports
Number of subjects: 79
Study: 26052677

Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 400

Group type: COMPARATOR
Intervention: MPI
Number of subjects: 400
Study: 23057804

Group type: EXPERIMENTAL
Intervention: IV ibuprofen (10 mg/kg on day 1, 5 mg/kg on day 2, and 5 mg/kg on day 3)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 21749238

Group type: EXPERIMENTAL
Intervention: Placebo-intervention condition (n = 188)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control condition (n = 160)
Number of subjects: 348
Study: 19488539

Group type: EXPERIMENTAL
Intervention: 0.5% racemic bupivacaine with vasoconstrictor
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.5% enantiomeric excess bupivacaine (S75-R25) with vasoconstrictor
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups (0.5% racemic bupivacaine and 0.5% enantiomeric excess bupivacaine)
Number of subjects: 50
Study: 17004191

Group type: EXPERIMENTAL
Intervention: Repithel
Number of subjects: 167

Group type: COMPARATOR
Intervention: Lipid gauze alone (Control)
Number of subjects: 167
Study: 12724244

Group type: EXPERIMENTAL
Intervention: Non-directive counselling
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy
Number of subjects: 193

Group type: COMPARATOR
Intervention: Routine primary care
Number of subjects: 193
Study: 11085197

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8756195

Group type: EXPERIMENTAL
Intervention: Suprapubic drainage (cistofix Ch 15)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Urethral catheterization (latex foley catheter)
Number of subjects: 52
Study: 1826912

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg/d)
Number of subjects: 20
Study: 6628498

Group type: EXPERIMENTAL
Intervention: Propranolol (2-16 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pindolol (0.2-1.6 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 31292608

Group type: EXPERIMENTAL
Intervention: levcromakalim (0.05 mg/min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: levcromakalim
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 28203319

Group type: EXPERIMENTAL
Intervention: Iron supplementation (37 mg of elemental iron daily for 3 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 25
Study: 25791612

Group type: EXPERIMENTAL
Intervention: Mirabegron administered as a single oral dose under fasted conditions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirabegron administered once daily under fed conditions for 8 days after a washout period.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirabegron administered with low-fat and high-fat meals.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirabegron in female subjects compared to male subjects.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safety and tolerability assessments of mirabegron.
Number of subjects: 0
Study: 23299853

Group type: EXPERIMENTAL
Intervention: Algorithm A
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Algorithm B
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control arm (C)
Number of subjects: 301
Study: 21174007

Group type: EXPERIMENTAL
Intervention: γ' fibrinogen levels
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Number of dental sites with tissue inflammation
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Total fibrinogen levels
Number of subjects: 284
Study: 19245306

Group type: EXPERIMENTAL
Intervention: Hypothermia (cooling to 35 degrees C and 33 degrees C)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Normothermia (standard management at normothermia)
Number of subjects: 240
Study: 17348435

Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (blood transfusions)
Number of subjects: 0
Study: 14679118

Group type: EXPERIMENTAL
Intervention: Cisplatin (25 mg/m²) and Docetaxel (20 mg/m²) administered on days 1, 8, and 15 every 4 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cisplatin and Docetaxel
Number of subjects: 34
Study: 11354452

Group type: EXPERIMENTAL
Intervention: Additional scrubbing of toe clefts with a gauze swab soaked in topical antiseptic.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard preparation with antiseptic between the toes.
Number of subjects: 50
Study: 9075034

Group type: EXPERIMENTAL
Intervention: Multi-orifice epidural catheters
Number of subjects: 872

Group type: COMPARATOR
Intervention: Single-orifice epidural catheters
Number of subjects: 872
Study: 7905101

Group type: EXPERIMENTAL
Intervention: Intraarterial infusion of 17 beta‐oestradiol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patch administration of 17 beta‐oestradiol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Discontinuation of oestradiol
Number of subjects: 18
Study: 3139909

Group type: EXPERIMENTAL
Intervention: 6 mg/kg Euphyllin (theophylline)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg Euphyllin (theophylline)
Number of subjects: 30
Study: 31490025

Group type: EXPERIMENTAL
Intervention: Prognostic DNA methylation biomarkers identified through RNA-seq analysis, including 567 CpG sites related to overall survival (OS) and 1,146 CpG site pairs related to OS.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Validation dataset for prognostic signatures.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein-protein interactions (PPI) network analysis of the CpG sites of the signature.
Number of subjects: 0
Study: 31060536

Group type: EXPERIMENTAL
Intervention: Loose alarm strategy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tight alarm strategy
Number of subjects: 21
Study: 28800341

Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training with anodal tDCS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 21
Study: 26292584

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (AVR)
Number of subjects: 795
Study: 22906685

Group type: EXPERIMENTAL
Intervention: Physostigmine (1 mg/h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 21707215

Group type: EXPERIMENTAL
Intervention: Gist-based reasoning triggered by retrieval cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbatim-based reasoning triggered by different retrieval cues
Number of subjects: 0
Study: 19085404

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 312

Group type: COMPARATOR
Intervention: High-quality train-and-place vocational rehabilitation (Control)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 312
Study: 16490028

Group type: EXPERIMENTAL
Intervention: Reactive hyperemic response (RHR) measurement in ED patients with concomitant CVD or risk factors
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Reactive hyperemic response (RHR) measurement in ED patients without CVD or risk factors
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 48
Study: 12560299

Group type: EXPERIMENTAL
Intervention: alfentanil 20 microg x kg(‐1), lidocaine 1.5 mg x kg(‐1), propofol 3 mg x kg(‐1) (Group I; n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: fentanyl 2 microg x kg(‐1), lidocaine 1.5 mg x kg(‐1), propofol 3 mg x kg(‐1) (Group II; n = 40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group I
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group II
Number of subjects: 80
Study: 10716371

Group type: EXPERIMENTAL
Intervention: 350 microg of the lipopeptide immunogen administered on days 0, 28, and 56 to HLA-selected subjects (4 subjects)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo administered according to a similar inoculation schedule to HLA-selected subjects (3 subjects)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 350 microg of the lipopeptide immunogen administered to HLA-mismatched subjects (2 subjects)
Number of subjects: 9
Study: 9179102

Group type: EXPERIMENTAL
Intervention: Routine individual feedback on test ordering behavior
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 8231034

Group type: EXPERIMENTAL
Intervention: 35 degrees C dialysate
Number of subjects: 12

Group type: COMPARATOR
Intervention: 37 degrees C dialysate
Number of subjects: 12
Study: 3544940

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg body weight diazepam (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.15 mg/kg body weight midazolam (Group B)
Number of subjects: 20
Study: 27491344

Group type: EXPERIMENTAL
Intervention: Walking (ten sets of 2‐min walking at the speed corresponding to the onset of claudication pain with 2‐min interval between sets)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combined exercise (1 × 10 reps in eight resistance exercises plus five‐two‐minute sets of walking)
Number of subjects: 13
Study: 26829083

Group type: EXPERIMENTAL
Intervention: 6-month home physiotherapy program
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study: 23887332

Group type: EXPERIMENTAL
Intervention: Balanced exercise program
Number of subjects: 54

Group type: COMPARATOR
Intervention: Educational program
Number of subjects: 54
Study: 22802599

Group type: EXPERIMENTAL
Intervention: bisGMA-based composite
Number of subjects: 534

Group type: COMPARATOR
Intervention: compomer
Number of subjects: 534

Group type: COMPARATOR
Intervention: amalgam
Number of subjects: 534
Study: 20354032

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 2622
Study: 17391383

Group type: EXPERIMENTAL
Intervention: Amoxycillin-clavulanic acid 625 mg, four times daily for 3 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Amoxycillin-clavulanic acid 625 mg, four times daily for 10 days
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 56
Study: 16141426

Group type: EXPERIMENTAL
Intervention: Dipyridamole/Aspirin (200 mg dipyridamole/25 mg aspirin twice a day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Aspirin (control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Dipyridamole/Aspirin
Number of subjects: 6
Study: 12164990

Group type: EXPERIMENTAL
Intervention: Chlorhexidine acetate/xylitol gum (ACHX)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Xylitol gum (X)
Number of subjects: 111

Group type: COMPARATOR
Intervention: No-gum (N)
Number of subjects: 111
Study: 10457579

Group type: EXPERIMENTAL
Intervention: Mensendieck exercise program (20 group sessions over 13 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (experience without intervention)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Mensendieck exercise program
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 8545530

Group type: EXPERIMENTAL
Intervention: Flumazenil 1.0 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 60
Study: 2349370

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 38
Study: 215011

Group type: EXPERIMENTAL
Intervention: Topical application of double stranded RNA from f2-phage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double-blind experiment
Number of subjects: 0
Study: 31626006

Group type: EXPERIMENTAL
Intervention: Tourniquet use during TKA
Number of subjects: 200

Group type: COMPARATOR
Intervention: No tourniquet use during TKA
Number of subjects: 200
Study: 28364615

Group type: EXPERIMENTAL
Intervention: Maximum strength (STR)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Muscle endurance (END)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (M-BEAST)
Number of subjects: 22
Study: 25693055

Group type: EXPERIMENTAL
Intervention: Corticosteroids for ∼9 months and a maximum of six 500‐mg fixed‐dose intravenous (IV) cyclophosphamide (CYC) pulses, every 2‐3 weeks, then maintenance azathioprine or methotrexate.
Number of subjects: 108

Group type: COMPARATOR
Intervention: Corticosteroids for ∼26 months combined with 500 mg/m2 IV CYC pulses, every 2‐3 weeks until remission, then maintenance for GPA or MPA patients and for those with EGPA or PAN with a Five‐Factors Score (FFS) of ≥1.
Number of subjects: 108
Study: 23457086

Group type: EXPERIMENTAL
Intervention: Motivational self-efficacy
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Volitional self-efficacy
Number of subjects: 373
Study: 21762149

Group type: EXPERIMENTAL
Intervention: Dental prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional clinical indices (Modified Gingival Index and Bleeding Index)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital impressions for gingival contour volume measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study: 19873911

Group type: EXPERIMENTAL
Intervention: Acupuncture at Baihui (GV 20), Danzhong (CV 17), Zhongwan (CV 12), Qihai (CV 6), Guanyuan (CV 4), Hegu (LI 4), Zusanli (ST 36), thrice a week for 14 sessions
Number of subjects: 70

Group type: COMPARATOR
Intervention: Acupuncture at non-meridian points (2 cm to the acupoints), thrice a week for 14 sessions
Number of subjects: 70
Study: 17761637

Group type: EXPERIMENTAL
Intervention: Integrated yoga program
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 15513324

Group type: EXPERIMENTAL
Intervention: Serum cardiac troponin T (cTnT)
Number of subjects: 26
Study: 11179125

Group type: EXPERIMENTAL
Intervention: Cumulative dose of salbutamol (400 microg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cumulative dose of salbutamol (800 microg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single dose of salbutamol (50, 100, or 400 microg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cumulative dose of salbutamol (50+50+100+200 or 100+100+200+400 or 400+0+0+0 or 0+0+0+0 microg)
Number of subjects: 24
Study: 9788413

Group type: EXPERIMENTAL
Intervention: Irradiation after biopsy/local excision
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Irradiation after partial/radical vulvectomy
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Irradiation with doses under 50 Gy in T1-2 tumors
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Irradiation with doses below 50 Gy in T3-4 tumors
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Irradiation after partial/radical vulvectomy in T1-2 tumors
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Irradiation after partial/radical vulvectomy in T3-4 tumors
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Postoperative irradiation after partial or radical lymph node dissection
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combined treatment of irradiation and wide local tumor excision
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Postradical vulvectomy irradiation
Number of subjects: 86
Study: 8141197

Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole gel 5 gm twice daily for 5 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole gel
Number of subjects: 90
Study: 3142242

Group type: EXPERIMENTAL
Intervention: Max EPA intake in coronary artery disease patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Max EPA intake in normal subjects
Number of subjects: 12
Study: 31556911

Group type: EXPERIMENTAL
Intervention: Cabozantinib s-maleate
Number of subjects: 119

Group type: COMPARATOR
Intervention: Mitoxantrone hydrochloride-prednisone
Number of subjects: 119
Study: 29852887

Group type: EXPERIMENTAL
Intervention: Higher CDQ scores for non-core foods (indicating higher consumption levels)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Parent-reported subscale score for fruit and vegetable intake
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Parent-reported subscale score for non-core food intake
Number of subjects: 396
Study: 27707496

Group type: EXPERIMENTAL
Intervention: Early, goal-directed mobilisation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 200
Study: 25973554

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38